U.S. government backs Mark Cuban company to develop ibogaine
The Department of Health and Human Services committed up to $4.9 million through ARPA-H for the project.

The U.S. Department of Health and Human Services announced it is backing the Mark Cuban Cost Plus Drug Company to develop ibogaine for post-traumatic stress disorder, according to Psychedelic Alpha. The agency is committing up to $4.9 million through ARPA-H to fund the work on manufacturing and government approvals.
Beond, a clinic operator, provided data to support the development effort. The project involves collaboration with the Department of Veterans Affairs. Officials also launched a funding opportunity through the National Institute of Mental Health to build a real-world research network.

Figures as reported by Psychedelic Alpha.







